EUDA Health Holdings Ltd. (EUDA) is asking shareholders to approve a dual-class structure, changing its authorized shares to an unlimited number of Class A ordinary shares and 2,000,000 Class B ordinary shares. The proposal would reclassify 437,824 shares held by Tan Meng Dong and affiliate 8i Capital Limited as Class B, along with 1,562,176 authorized but unissued shares. Each Class B share would carry 50 votes, compared with one vote per Class A share.
If the proposals are approved and the amended memorandum and articles are filed, Tan Meng Dong and 8i Capital would hold 437,824 Class B shares, representing approximately 14.6% of outstanding shares and approximately 89.5% of voting power. These figures exclude 14,000 Class A shares held in escrow without voting rights. Shareholders will also vote on adopting the amended governing documents and allowing adjournment to permit further proxy solicitation. The virtual meeting is scheduled for October 30, 2026; proxies must be received before 11:59 p.m. Eastern Time on October 29, 2026.
EUDA Health Holdings Ltd filed an amendment to its Amended and Restated Memorandum of Association and Articles of Association with the British Virgin Islands Registrar of Corporate Affairs on October 5, 2026. A copy of the company’s current amended and restated documents was attached.
EUDA Health Holdings Limited reported revenue of $3,467,835 for the six months ended June 30, 2026, compared with $3,057,323 in the same 2025 period. Net loss narrowed to $796,950 from $1,201,696. Property management services generated $2,255,161, and holistic wellness consumer products and services generated $1,212,674. Net cash used in operating activities was $1,206,041; cash and cash equivalents were $365,904 at June 30, 2026.
EUDA reported 16,000,000 QB Tokens at a fair value of $7,560,000 as of June 30, 2026, after obtaining control on May 19, 2026; consideration was $250,000 cash and 500,000 ordinary shares. The company also reported $3,750,000 of proceeds from issuing 625,000 ordinary shares through a direct offering. Management cited working capital of approximately $5.5 million and determined that conditions raise substantial doubt about EUDA’s ability to continue as a going concern within one year after issuance of the financial statements.
EUDA Health Holdings Limited describes a planned collaboration under a non-binding Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. The parties plan to combine GO POSB’s induced pluripotent stem cell platform and universal tumor organoid bank with SIIT’s Natural Killer and NK-TCR cell engineering and GMP manufacturing capabilities to explore off-the-shelf cell therapies for wellness and oncology.
The initiative targets future global distribution, subject to definitive agreements, sufficient funding, manufacturing, testing, clinical evaluation and regulatory approvals. EUDA positions this program within its strategy as a distributor of wellness and non-invasive healthcare products in Asia, aiming to address the needs of over 1.8 billion people in a region where more than 30% of the population is rapidly aging.
EUDA Health Holdings Limited entered into a tri-party Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. to collaborate on next-generation therapies derived from induced pluripotent stem cells, including NK-TCR cell therapies.
The company states this collaboration is a significant milestone that aligns with its strategy to strengthen commercialization and distribution of innovative, science-backed wellness and non-invasive healthcare products and services. EUDA focuses on Singapore, Malaysia and China and aims to serve over 1.8 billion people in a region where more than 30% of the population is rapidly aging, with an emphasis on the longevity sector.
Euda Health Holdings Limited reports that it has terminated its at-the-market equity offering program and the related At The Market Offering Agreement with Chardan Capital Markets, LLC. The program had previously allowed sales of ordinary shares with an aggregate offering price of up to $10.0 million, but this capacity had been reduced to zero and no ordinary shares were sold. All related prospectus supplements are also terminated as of the date of this supplement. The company’s ordinary shares trade on the NASDAQ Capital Market under the symbol EUDA, and the closing price was $15.30 on July 21, 2026.
EUDA Health Holdings filed a prospectus supplement to amend its prior ATM registration, reducing the maximum aggregate offering price to $10.0 million and suspending further sales under the ATM Agreement. The company states that no ordinary shares have been sold under the ATM Agreement as of the date of this Supplement. The company notified the manager on June 5, 2026 of its intent to terminate the ATM Agreement; the termination becomes effective 30 business days after that notice per the agreement. The supplement notes the Nasdaq closing price of the ordinary shares was $15.50 on June 11, 2026.
EUDA Health Holdings Limited is suspending and terminating its at-the-market equity offering program with Chardan Capital Markets LLC. The company had the ability to offer and sell up to $10,000,000 of ordinary shares under an At The Market Offering Agreement and related prospectus supplements.
EUDA sent a termination notice for the ATM Agreement on June 5, 2026, with termination to take effect on July 22, 2026 after a 30-business-day period. The ATM Offering has been suspended effective June 10, 2026, and EUDA plans to file a prospectus supplement reducing the number of shares offered to zero. As of this report, no ordinary shares have been sold under the ATM program.
EUDA Health Holdings Ltd reports an amended Schedule 13G showing beneficial ownership by Tan Meng Dong (James) and 8i Capital Limited. Mr. Tan beneficially owns 459,130 ordinary shares, equal to 15.3% of the outstanding ordinary shares; this total includes 340,631 shares held directly, 111,193 shares held by 8i Capital Limited, and 7,306 shares underlying warrants. The filing states 2,994,325 ordinary shares outstanding as of May 22, 2026. The statement notes that Mr. Tan is sole shareholder and director of 8i Capital Limited and that the parties filed a Joint Filing Agreement to report ownership jointly.